

FIVE THINGS TO KNOW ABOUT ...

Hypothyroidism

Anna M. Sawka MD PhD, Jacqueline Jonklaas MD PhD


Choosing Wisely Canada

In partnership with the Canadian Medical Association

In screening for primary hypothyroidism, only serum thyroid-stimulating hormone is required as a first-line test¹⁻³

In the general adult population (excluding pregnant women and older people), a normal thyroid-stimulating hormone (TSH) level is defined as the 95% laboratory-specific reference interval (about 0.45–4.50 mIU/L).¹⁻³ In adults (other than in pregnancy), TSH values greater than 10 mIU/L or TSH elevations with low free thyroxine values are generally considered indications for levothyroxine treatment¹⁻⁴ (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.141596/-/DC1).

About a third of patients receiving treatment for hypothyroidism have TSH values outside the target range¹⁻³

Annual TSH monitoring, with more frequent monitoring in special circumstances (e.g., pregnancy, major weight change or addition of potentially interacting medications), may facilitate appropriate dose adjustment.^{3,4} If needed, the levothyroxine dose may be titrated with changes of about 12.5–25 µg, measuring TSH about four to eight weeks later.^{1,4}

CMAJ is collaborating with Choosing Wisely Canada (www.choosingwiselycanada.org), with support from Health Canada, to publish a series of articles describing how to apply the Choosing Wisely Canada recommendations in clinical practice.

Maintenance of a normal serum TSH level is the mainstay of biochemical follow-up of primary hypothyroidism

In general, maintenance of a normal TSH level (about 0.45–4.50 mIU/L) is the biochemical goal in primary hypothyroidism (Box 1);⁵ age-specific target TSH levels have been recommended.¹⁻⁴ Higher upper limits of TSH targets are acceptable for older people (e.g., up to 6 mIU/L in patients aged > 65 yr, with consideration of comorbidities).^{2,3}

Box 1: Choosing Wisely Canada recommendation on hypothyroidism

- Don't use free thyroxine or triiodothyronine to screen for hypothyroidism, or to monitor and adjust levothyroxine (thyroxine) dose in patients with known primary hypothyroidism.⁵

Coingestion of levothyroxine with food may cause impaired absorption and should be avoided^{1,3}

Ideally, levothyroxine should be taken only with water at a consistent time, either one hour before breakfast or at bedtime more than three hours after the final meal of the day.^{1,3} If an alternative schedule is chosen, it should be consistently maintained.

References

1. Garber JR, Cobin RH, Gharib H, et al. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Endocr Pract* 2012;18:988-1028.
2. Brenta G, Vaisman M, Sgarbi JA, et al. Task Force on Hypothyroidism of the Latin American Thyroid Society (LATS). Clinical practice guidelines for the management of hypothyroidism. *Arq Bras Endocrinol Metabol* 2013;57:265-91.
3. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. *Thyroid* 2014;24:1670-751.
4. Pearce SHA, Brabant G, Duntas LH, et al. 2013 ETA Guideline: management of subclinical hypothyroidism. *Eur Thy J* 2013;2:215-28.
5. Canadian Society of Endocrinology and Metabolism. Five things physicians and patients should question. Choosing Wisely Canada; 2014. Available: www.choosingwiselycanada.org/recommendations/endocrinology-and-metabolism (accessed 2015 Jan. 12).

Coingestion of levothyroxine with medications or dietary supplements that may interfere with its absorption should be avoided^{2,3}

Some medications (e.g., bile acid sequestrants, phosphate binders, aluminum-containing antacids) and dietary supplements (e.g., calcium, iron) may interfere with levothyroxine absorption. Ideally, a four-hour separation from taking levothyroxine is advised.^{2,3} Lists of drugs that interfere are available.^{1,3}

Competing interests: Anna Sawka is a member and Jacqueline Jonklaas is chair of the American Thyroid Association Thyroid Replacement Task Force (unpaid). Jacqueline Jonklaas holds an R01 research grant from the National Institutes of Health for hypothyroidism treatment in aging and thyroid cancer.

This article has been peer reviewed.

Affiliations: Division of Endocrinology and Metabolism (Sawka), Department of Medicine, and University Health Network, University of Toronto, Toronto, Ont.; Division of Endocrinology and Metabolism (Jonklaas), Department of Medicine, Georgetown University, Washington, DC

Acknowledgements: The authors thank Dr. Shereen Ezzat, of the University Health Network and the University of Toronto, for reviewing the manuscript.

Correspondence to: Anna Sawka, sawkaam@yahoo.com

CMAJ 2015. DOI:10.1503/cmaj.141596